DexCom, Inc.
Will Medicare coverage for type 2 patients not using insulin arrive soon enough to speed growth back up, or does DexCom settle into low-double-digit sales growth?
Last 4 earnings calls · through Q2 FY2026
Bull case
Covered patients not using CGM
The bull case is that insurance already pays for far more people than use CGM, so growth depends on converting covered patients rather than winning new coverage.
Trial evidence for payer talks
The bull case is that strong randomized trial evidence in non-insulin patients is the company's best argument for persuading Medicare and foreign payers to pay.
Longer wear lifts satisfaction
The bull case is that longer wear time and better accuracy have raised customer satisfaction, which the company expects to support retention and steady sensor use.
Cash flow funds buybacks
Rising free cash flow and wider margins fund large share repurchases, so per-share results can grow faster than revenue even if sales growth slows.
Bear case
U.S. growth near market rate
The bear case is that the U.S. business now grows only about as fast as the overall market, so it needs new coverage rather than better selling to reaccelerate.
Medicare coverage timing
The bear case is that Medicare coverage for people with diabetes not using insulin is expected to take effect only in the middle of next year, leaving a long gap before revenue arrives.
Lower-priced tender volume
The bear case is that much of the international growth comes from tenders and cheaper product versions, which bring patients but less revenue per patient than the core U.S. business.
Factory and input costs
Input costs and the startup of a new factory weigh on gross margin, so the margin recovery depends on costs that management does not fully control.
Bull and bear points
Growth & Execution
In short: Coverage keeps widening and new sensors are launching, but U.S. growth has slowed toward the market rate.
Four largest PBMs now cover CGM for all people with diabetes
National formulary coverage takes effect immediately at the pharmacy, and management says it puts more than 7 million type 2 non-insulin patients within reach. That widens the pool of patients the sales force can convert without any government decision.
Q2 FY2026 callG7 15-day conversion on track for half the U.S. base
Management expects nearly half the U.S. base on the newer sensor by year end. Starting next year with a converted base means the longer-wear product contributes more to margin as it becomes the routine purchase.
Q2 FY2026 call
Revenue growth has slowed to low double digits
Worldwide revenue grew 13% last quarter, below the pace of recent years, and guidance assumes the coverage landscape stays as it is today. Faster growth now depends on decisions the company does not control.
Q4 FY2025 callRecord new-patient language has softened
A year ago management told analysts to assume a record year of new patients. It now describes starts as in line with the prior record, with U.S. starts only up sequentially, which leaves less cushion under the growth guidance.
Tone shiftQ3 FY2025 → Q2 FY2026
Profitability & Financial Strength
In short: Margins and free cash flow are expanding and fund buybacks, while factory and input costs may reverse that.
Gross margin recovering as scrap and freight normalize
Gross margin rose nearly four points from a year earlier as ocean shipping returned and scrapped sensors fell. Management raised full-year gross margin guidance to approximately 64%.
Q2 FY2026 callFree cash flow funds a large share repurchase
Free cash flow over the last year equaled 28% of revenue, and the company repurchased stock while settling a convertible bond in cash. Fewer shares mean per-share earnings grow faster than operating profit.
Filed financials
New Irish factory depresses margin before it helps
Hiring, training and depreciation at the Ireland plant run through operating expense this year and move into cost of goods once production starts in the fourth quarter, so management expects gross margin to step down at that point.
Q4 FY2025 callFuel and resin prices put margins at risk
Management left gross margin guidance unchanged despite a strong first quarter, setting aside room for oil-linked fuel and resin costs that reach the income statement with a lag. Guidance already absorbs that potential cost.
Q1 FY2026 call
Market Position
In short: Trial evidence and unused coverage are strong, while Medicare timing and tender pricing limit the payoff.
Randomized trial in non-insulin type 2 met its goals
The CONNECT trial showed a 0.9 point A1C advantage over standard care in people with type 2 diabetes not using insulin. That is the caliber of evidence that has previously moved clinical guidelines and payer decisions.
Q2 FY2026 callMost people with U.S. coverage for CGM do not use it
Roughly 9 million Americans have insurance coverage for CGM and are not using it, before any new coverage decision. That leaves growth available from better selling into existing coverage rather than relying on Medicare.
Q2 FY2026 call
Medicare coverage timing has moved later
Earlier management said it was building capacity as if a Medicare decision could come at any moment. It now expects a decision by the end of this year and coverage taking effect in the middle of 2027, which pushes the revenue out.
Tone shiftQ4 FY2025 → Q2 FY2026International growth leans on lower-priced tender wins
Dexcom ONE+ and Flex win tenders that were previously closed, but at price points below the U.S. business. A larger share of growth therefore comes from patients who generate less revenue each.
Q4 FY2025 call